

Giuseppe Di Lorenzo

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1155717/giuseppe-di-lorenzo-publications-by-year.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

274 papers	6,047 citations	44 h-index	61 g-index
311 ext. papers	7,139 ext. citations	4.5 avg, IF	5.45 L-index

#	Paper	IF	Citations
274	Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis.. <i>European Urology</i> , 2022 ,	10.2	2
273	Liquid biopsy in bladder cancer: State of the art and future perspectives.. <i>Critical Reviews in Oncology/Hematology</i> , 2022 , 170, 103577	7	7
272	Re: Matthew R. Smith, Maha Hussain, Fred Saad, et al. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. <i>N Engl J Med</i> . In press. https://doi.org/10.1056/NEJMoa2119115 .. <i>European Urology</i> , 2022 , 82, e17-e17	10.2	0
271	Kaempferol, Myricetin and Fisetin in Prostate and Bladder Cancer: A Systematic Review of the Literature. <i>Nutrients</i> , 2021 , 13,	6.7	8
270	Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional Analysis. <i>Frontiers in Oncology</i> , 2021 , 11, 651745	5.3	4
269	First-line systemic therapy for metastatic castration-sensitive prostate cancer: An updated systematic review with novel findings. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 157, 103198	7	11
268	A risk-group classification model in patients with bladder cancer under neoadjuvant cisplatin-based combination chemotherapy. <i>Future Oncology</i> , 2021 , 17, 3987-3994	3.6	2
267	Clinical Outcomes of Platinum-ineligible Patients with Advanced Urothelial Carcinoma Treated With First-line PD1/L1 Inhibitors. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, 425-433	3.3	4
266	Assessment of Total, PTEN, and AR-V7 Circulating Tumor Cell Count by Flow Cytometry in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, e286-e298	3.3	6
265	Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. <i>JAMA Network Open</i> , 2020 , 3, e2021692	10.4	19
264	Coronavirus Disease (COVID-19) in Italy: Analysis of Risk Factors and Proposed Remedial Measures. <i>Frontiers in Medicine</i> , 2020 , 7, 140	4.9	29
263	Type 2 diabetes mellitus predicts worse outcomes in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 459-464	2.8	26
262	Re: Olaparib for Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2020 , 78, 767-768	10.2	1
261	Management of Ewing Sarcoma Family of Tumors: A Short Description of a Rare Primitive Uterine pPNET and Literature Review. <i>OncoTargets and Therapy</i> , 2020 , 13, 1179-1184	4.4	1
260	Outcomes Associated with First-Line anti-PD-1/ PD-L1 agents vs. Sunitinib in Patients with Sarcomatoid Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2020 , 12,	6.6	19
259	Re: Silke Gillissen Sommer, Thomas Powles. Advice for Medical Oncology Care of Urological Cancer Patients During the COVID-19 Pandemic. <i>Eur Urol</i> 2020;78:e2-3: Is It Always Correct to Continue Androgen Receptor Signaling Inhibitors in the COVID-19 Era?. <i>European Urology</i> , 2020 , 78, e10-e11	10.2	3
258	Coronavirus Disease 2019 Emergency and Cancer in the South of Italy: What's New for the Oncologist?. <i>Frontiers in Medicine</i> , 2020 , 7, 189	4.9	0

257	COVID 19 therapies and anti-cancer drugs: A systematic review of recent literature. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 152, 102991	7	23
256	Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 151, 102992	7	11
255	Hematological Toxicity During Concomitant Treatment With Ruxolitinib and Avelumab for Merkel Cell Carcinoma. <i>Frontiers in Oncology</i> , 2020 , 10, 579914	5.3	2
254	Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor. <i>World Journal of Urology</i> , 2020 , 38, 143-150	4	31
253	Effect of Baseline Characteristics on Cabazitaxel Treatment Duration in Patients with Metastatic Castration-Resistant Prostate Cancer: A Post Hoc Analysis of the Compassionate Use/Expanded Access Programs and CAPRISTANA Registry. <i>Cancers</i> , 2020 , 12,	6.6	1
252	Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results. <i>Journal of Translational Medicine</i> , 2019 , 17, 296	8.5	7
251	Predictors of Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Receiving EGFR Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2019 , 11,	6.6	12
250	Metabolomic profiling for the identification of novel diagnostic markers and therapeutic targets in prostate cancer: an update. <i>Expert Review of Molecular Diagnostics</i> , 2019 , 19, 377-387	3.8	28
249	The Evolving Systemic Treatment Landscape for Patients with Advanced Prostate Cancer. <i>Drugs</i> , 2019 , 79, 381-400	12.1	15
248	Management of kidney cancer patients: 2018 guidelines of the Italian Medical Oncology Association (AIOM). <i>Tumori</i> , 2019 , 105, 3-12	1.7	7
247	First-line PD1/PD-L1 inhibitors for platinum-ineligible advanced urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 432-432	2.2	1
246	Real-world experience with cabazitaxel in patients with metastatic castration-resistant prostate cancer: a final, pooled analysis of the compassionate use programme and early access programme. <i>Oncotarget</i> , 2019 , 10, 4161-4168	3.3	5
245	Bone-targeted therapy in castration-resistant prostate cancer: where do we stand?. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2019 , 71, 445-456	4.4	4
244	A randomized phase II study comparing cabazitaxel/prednisone to cabazitaxel alone in docetaxel-pretreated men with metastatic castration resistant prostate cancer (mCRPC): The CABACARE trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS345-TPS345	2.2	
243	Biomarkers of Prognosis and Efficacy of Anti-angiogenic Therapy in Metastatic Clear Cell Renal Cancer. <i>Frontiers in Oncology</i> , 2019 , 9, 1400	5.3	21
242	Genetics and management of locally advanced carcinomas of the head and neck: role of altered fractionation radiotherapy. <i>Future Science OA</i> , 2019 , 5, FSO347	2.7	2
241	Incidence of fatigue and low-dose corticosteroid use in prostate cancer patients receiving systemic treatment: a meta-analysis of randomized controlled trials. <i>World Journal of Urology</i> , 2019 , 37, 1049-1059	4	4
240	Statin Use and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Abiraterone Acetate. <i>European Urology Focus</i> , 2018 , 4, 874-879	5.1	15

239	Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-Line Sunitinib (QUASAR): Results of a Phase I Trial. <i>Frontiers in Pharmacology</i> , 2018 , 9, 189	5.6	12
238	Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study. <i>Oncotarget</i> , 2018 , 9, 19861-19873	3.3	17
237	It is no longer the time to disregard thyroid metastases from breast cancer: a case report and review of the literature. <i>BMC Cancer</i> , 2018 , 18, 146	4.8	9
236	A randomized phase II study comparing cabazitaxel/prednisone to cabazitaxel alone for second-line chemotherapy in men with metastatic castrate resistant prostate cancer (mCRPC): CABACARE.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS387-TPS387	2.2	0
235	High-dose fotemustine in temozolomide-pretreated glioblastoma multiforme patients: A phase I/II trial. <i>Medicine (United States)</i> , 2018 , 97, e11254	1.8	7
234	Predictors of Residual T1 High Grade on Re-Transurethral Resection in a Large Multi-Institutional Cohort of Patients with Primary T1 High-Grade/Grade 3 Bladder Cancer. <i>Journal of Cancer</i> , 2018 , 9, 4250-4254	4.5	18
233	Development of a Lumped Parameter Model for an Aeronautic Hybrid Electric Propulsion System. <i>Aerospace</i> , 2018 , 5, 105	2.5	8
232	Nonmotor Symptoms in Parkinson Disease: A Descriptive Review on Social Cognition Ability. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2017 , 30, 109-121	3.8	34
231	Epigenetic control of gene expression: Potential implications for cancer treatment. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 111, 166-172	7	79
230	Locally advanced paranasal sinus carcinoma: A study of 30 patients. <i>Oncology Letters</i> , 2017 , 13, 1338-1342	4.6	4
229	PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide: A retrospective case-report study. <i>Medicine (United States)</i> , 2017 , 96, e6817	1.8	1
228	Clinical Outcomes of Perioperative Chemotherapy in Patients With Locally Advanced Penile Squamous-Cell Carcinoma: Results of a Multicenter Analysis. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 548-555.e3	3.3	24
227	Modelling of a Hybrid-Electric Light Aircraft. <i>Energy Procedia</i> , 2017 , 126, 1155-1162	2.3	8
226	The Influence of Prednisone on the Efficacy of Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Cancer</i> , 2017 , 8, 2663-2668	4.5	4
225	The emerging role of obesity, diet and lipid metabolism in prostate cancer. <i>Future Oncology</i> , 2017 , 13, 285-293	3.6	37
224	The Sooner, the Better: The Establishment of a Treatment Paradigm in Prostate Cancer. <i>Frontiers in Pharmacology</i> , 2017 , 8, 788	5.6	2
223	Low serum total testosterone level as a predictor of upstaging and upgrading in low-risk prostate cancer patients meeting the inclusion criteria for active surveillance. <i>Oncotarget</i> , 2017 , 8, 18424-18434	3.3	44
222	Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis. <i>Oncotarget</i> , 2017 , 8, 100708-100716	3.3	20

221	Testicular cancer from diagnosis to epigenetic factors. <i>Oncotarget</i> , 2017 , 8, 104654-104663	3.3	36
220	Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate or enzalutamide.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e16503-e16503	2.2	
219	A Challenging Surgical Approach to Locally Advanced Primary Urethral Carcinoma: A Case Report and Literature Review. <i>Medicine (United States)</i> , 2016 , 95, e3642	1.8	4
218	Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer. <i>Future Oncology</i> , 2016 , 12, 493-502	3.6	6
217	Biomarkers in localized prostate cancer. <i>Future Oncology</i> , 2016 , 12, 399-411	3.6	27
216	Thermal and fluid dynamic behaviors of confined laminar impinging slot jets with nanofluids. <i>International Communications in Heat and Mass Transfer</i> , 2016 , 70, 15-26	5.8	36
215	Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma. <i>European Urology</i> , 2016 , 69, 634-641	10.2	47
214	Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma. <i>Journal of Urology</i> , 2016 , 195, 277-82	2.5	40
213	Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma. <i>Oncotarget</i> , 2016 , 7, 33381-90	3.3	10
212	Impact of prior platinum on patients receiving salvage systemic therapy for advanced urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 386-386	2.2	
211	Prognostic and Predictive Factors in Patients with Advanced Penile Cancer Receiving Salvage (2nd or Later Line) Systemic Treatment: A Retrospective, Multi-Center Study. <i>Frontiers in Pharmacology</i> , 2016 , 7, 487	5.6	14
210	Combination therapy for metastatic renal cell carcinoma. <i>Annals of Translational Medicine</i> , 2016 , 4, 100	3.2	16
209	Complete Response and Fatigue Improvement With the Combined Use of Cyclophosphamide and Quercetin in a Patient With Metastatic Bladder Cancer: A Case Report. <i>Medicine (United States)</i> , 2016 , 95, e2598	1.8	12
208	Complications and quality of life in elderly patients with several comorbidities undergoing cutaneous ureterostomy with single stoma or ileal conduit after radical cystectomy. <i>BJU International</i> , 2016 , 118, 521-6	5.6	36
207	Docetaxel Rechallenge in a Heavily Pretreated Patient With Castration-Resistant Prostate Cancer: A Case Report and Review of Literature. <i>Medicine (United States)</i> , 2016 , 95, e2754	1.8	2
206	Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, 494-498	3.3	1
205	Cisplatin- Versus Non-Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, 331-40	3.3	9
204	Lack of Cumulative Toxicity Associated With Cabazitaxel Use in Prostate Cancer. <i>Medicine (United States)</i> , 2016 , 95, e2299	1.8	13

203	Contemporary molecular tests for prognosis and treatment guidance for castration-resistant prostate cancer. <i>Expert Review of Molecular Diagnostics</i> , 2016 , 16, 1113-1120	3.8	5
202	The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review. <i>Expert Opinion on Biological Therapy</i> , 2016 , 16, 1387-1401	5.4	16
201	Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors. <i>Annals of Surgical Oncology</i> , 2015 , 22, 2094-100	3.1	48
200	Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis. <i>Annals of Oncology</i> , 2015 , 26, 2107-13	10.3	66
199	Cisplatin-based first-line therapy for advanced urothelial carcinoma after previous perioperative cisplatin-based therapy. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 178-84	3.3	12
198	Clinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and younger. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 265.e15-21	2.8	6
197	Antagonistic effects of chloroquine on autophagy occurrence potentiate the anticancer effects of everolimus on renal cancer cells. <i>Cancer Biology and Therapy</i> , 2015 , 16, 567-79	4.6	44
196	Rapidly progressive disease in a castration-resistant prostate cancer patient after cabazitaxel discontinuation. <i>Anti-Cancer Drugs</i> , 2015 , 26, 236-9	2.4	6
195	Everolimus as second-line therapy for metastatic renal cell carcinoma: a real-life study. <i>Future Oncology</i> , 2015 , 11, 219-24	3.6	7
194	Incomplete Cross-Resistance Between Taxanes for Advanced Urothelial Carcinoma: Implications for Clinical Practice and Trial Design. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 250-6	3.3	5
193	The expanding role of chemotherapy in prostate cancer. <i>Future Oncology</i> , 2015 , 11, 2637-2640	3.6	1
192	Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer. <i>Future Oncology</i> , 2015 , 11, 3091-8	3.6	16
191	The use of interferon in melanoma patients: a systematic review. <i>Cytokine and Growth Factor Reviews</i> , 2015 , 26, 203-12	17.9	43
190	Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma. <i>Journal of Urology</i> , 2015 , 193, 41-7	2.5	43
189	Impact of the number of prior lines of therapy and prior perioperative chemotherapy in patients receiving salvage therapy for advanced urothelial carcinoma: implications for trial design. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 71-9	3.3	9
188	Modified Glasgow Prognostic Score is Associated With Risk of Recurrence in Bladder Cancer Patients After Radical Cystectomy: A Multicenter Experience. <i>Medicine (United States)</i> , 2015 , 94, e1861	1.8	39
187	Retrospective analysis on safety and efficacy of everolimus in treatment of metastatic renal cancer patients receiving dialysis. <i>Future Oncology</i> , 2015 , 11, 3159-66	3.6	9
186	Third-Line Chemotherapy for Metastatic Urothelial Cancer: A Retrospective Observational Study. <i>Medicine (United States)</i> , 2015 , 94, e2297	1.8	13

185	Adjuvant treatment in patients at high risk of recurrence of thymoma: efficacy and safety of a three-dimensional conformal radiation therapy regimen. <i>OncoTargets and Therapy</i> , 2015 , 8, 1345-9	4.4	4
184	Cosmic radiation and cancer: is there a link?. <i>Future Oncology</i> , 2015 , 11, 1123-35	3.6	10
183	Increased Expression of the Autocrine Motility Factor is Associated With Poor Prognosis in Patients With Clear Cell-Renal Cell Carcinoma. <i>Medicine (United States)</i> , 2015 , 94, e2117	1.8	34
182	Words of Wisdom. Re: Androgen Deprivation Therapy plus Docetaxel and Estramustine Versus Androgen Deprivation Therapy Alone for High-risk Localised Prostate Cancer (GETUG 12): A Phase 3 Randomised Controlled Trial. <i>European Urology</i> , 2015 , 68, 1098-9	10.2	
181	Increased risk of bladder cancer in critical areas at high pressure of pollution of the Campania region in Italy: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 96, 534-41	7	27
180	Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinoma. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 185-92	3.3	2
179	Prognostic factors in patients receiving third line targeted therapy for metastatic renal cell carcinoma. <i>Journal of Urology</i> , 2015 , 193, 1905-10	2.5	9
178	Complete remission (CR) during treatment for metastatic renal cell carcinoma (mRCC) with tyrosine kinase inhibitors (TKIs).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15594-e15594	2.2	1
177	Impact of new agents (NAs) on post-docetaxel (DOC) survival of octogenarians with metastatic castration resistant prostate cancer (mCRPC) patients (pts): Results of an Italian multicenter retrospective study (DELPHI study).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e16017-e16017	2.2	1
176	Improved prognostic classification of patients receiving salvage systemic therapy for advanced urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 311-311	2.2	1
175	Predicting Pathological Features at Radical Prostatectomy in Patients with Prostate Cancer Eligible for Active Surveillance by Multiparametric Magnetic Resonance Imaging. <i>PLoS ONE</i> , 2015 , 10, e0139696	3.7	29
174	Impact of first-line cisplatin versus non-cisplatin based chemotherapy on progression-free survival in patients with advanced urothelial carcinoma previously treated with perioperative cisplatin based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 335-335	2.2	
173	Safety of cisplatin in patients with urothelial carcinoma (UC) and renal dysfunction.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 321-321	2.2	
172	Multivariable analysis of predictors of side effects of cabazitaxel in the Italian Expanded Access Program.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 225-225	2.2	
171	Externally validated improved 5-factor prognostic model in patients (pts) receiving salvage systemic therapy for advanced urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4527-4527	2.3	
170	Myrtucommulone production by a strain of <i>Neofusicoccum australe</i> endophytic in myrtle (<i>Myrtus communis</i>). <i>World Journal of Microbiology and Biotechnology</i> , 2014 , 30, 1047-52	4.4	15
169	New agents for prostate cancer. <i>Annals of Oncology</i> , 2014 , 25, 1700-1709	10.3	43
168	Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel. <i>European Journal of Cancer</i> , 2014 , 50, 1617-27	7.5	120

167	Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, 395-8	3.3	11
166	Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib. <i>Canadian Urological Association Journal</i> , 2014 , 8, E121-5	1.2	7
165	Carboplatin plus etoposide in heavily pretreated castration-resistant prostate cancer patients. <i>Future Oncology</i> , 2014 , 10, 1353-60	3.6	21
164	Capecitabine plus gemcitabine in thymic epithelial tumors: final analysis of a Phase II trial. <i>Future Oncology</i> , 2014 , 10, 2141-7	3.6	21
163	Magnetic resonance spectroscopy: an in vivo molecular imaging biomarker for Parkinson's disease?. <i>BioMed Research International</i> , 2014 , 2014, 519816	3	21
162	Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2014 , 10, 975-83	3.6	38
161	A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma. <i>BJU International</i> , 2014 , 113, E137-43	5.6	28
160	Using cumulative toxicity to identify the optimal second-line targeted therapy in patients with metastatic renal cell carcinoma: what's new?. <i>Future Oncology</i> , 2014 , 10, 845-50	3.6	2
159	Urotensin II receptor determines prognosis of bladder cancer regulating cell motility/invasion. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014 , 33, 48	12.8	23
158	Prognostic risk stratification derived from individual patient level data for men with advanced penile squamous cell carcinoma receiving first-line systemic therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 501-8	2.8	25
157	Concurrent chemoradiotherapy for men with locally advanced penile squamous cell carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, 440-6	3.3	26
156	Poor survival in prostate cancer patients with primary refractoriness to docetaxel. <i>European Urology</i> , 2014 , 65, 505-7	10.2	17
155	Capecitabine plus gemcitabine in thymic epithelial tumors: Final analysis of a phase II trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 7528-7528	2.2	2
154	Impact of prior platinum agent and site of primary in patients with advanced urothelial carcinoma (UC) receiving salvage therapy.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 336-336	2.2	1
153	Impact of number of lines of prior chemotherapy in patients (pts) with advanced urothelial carcinoma (UC) receiving salvage therapy.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 353-353	2.2	1
152	Retrospective observational study of sunitinib administered on schedule 2/1 in patients with metastatic renal cell carcinoma (mRCC): The rainbow study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 471-471	2.2	7
151	Clinical outcomes of patients (pts) age 80 or older treated with docetaxel (DOC) as first-line chemotherapy for castration-resistant prostate cancer (CRPC): Results of an Italian multicenter retrospective study (DELPHI study).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 92-92	2.2	2
150	Squamous cell carcinoma of the scrotum: A look beyond the chimneystacks. <i>World Journal of Clinical Cases</i> , 2014 , 2, 654-60	1.6	17

149	Cabazitaxel in castration resistant prostate cancer with brain metastases: 3 case reports. <i>World Journal of Clinical Cases</i> , 2014 , 2, 228-31	1.6	15
148	Optimal management of a patient with recurrent nasopharyngeal carcinoma. <i>World Journal of Clinical Cases</i> , 2014 , 2, 297-300	1.6	8
147	Chemoradiation for locally advanced penile squamous cell carcinoma (PSCC): A multi-institution retrospective study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e15616-e15616	2.2	
146	Treatment and outcome(s) of a large cohort of Italian patients (pts) with poor-risk metastatic renal cell carcinoma (prRCC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, e15568-e15568	2.2	
145	Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma (UC) based on the impact of prognostic factors.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4514-4514	2.2	
144	A case series of low-dose sorafenib plus tamoxifen in sorafenib-pretreated patients with advanced hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e15139-e15139	2.2	
143	A proposed new model for prognostic stratification of poor-risk patients with metastatic renal cell carcinoma (mRCC) in the era of targeted therapy.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e15588-e15588 ^{2.2}	2.2	
142	Prognostic factors in patients with pancreatic metastases from renal cell carcinoma (PM-RCC): Room for thinking about the role of surgery?. <i>Journal of Clinical Oncology</i> , 2014 , 32, e15563-e15563	2.2	
141	Clinical outcomes of patients (pts) age 60 or younger treated with docetaxel (DOC) for castration-resistant prostate cancer (CRPC): Results of an Italian multicenter retrospective study (CYCLOP study).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 214-214	2.2	
140	Cohort compassionate-use program (CUP) and early access program (EAP) with cabazitaxel (Cbz) plus prednisone (P; Cbz + P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D): Analysis by age group.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 168-168	2.2	
139	Differences in terms of progression-free survival (PFS) and overall survival (OS) in patients treated with first-line sorafenib, sunitinib, and pazopanib for late relapsing (>5 years) renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 421-421	2.2	
138	Integrated comprehensive high-throughput kinomics profiling and whole exome sequencing of penile squamous cell cancer (PSCC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 383-383	2.2	
137	Regional analysis of a cohort compassionate-use program (CUP) and early access program (EAP) with cabazitaxel (Cbz) plus prednisone (P; Cbz + P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 242-242	2.2	0
136	Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy. <i>Prostate</i> , 2013 , 73, 227-35	4.2	51
135	Words of wisdom: Re: Abiraterone in metastatic prostate cancer without previous chemotherapy. <i>European Urology</i> , 2013 , 63, 961	10.2	3
134	Cytosolic phosphorylated EGFR is predictive of recurrence in early stage penile cancer patients: a retrospective study. <i>Journal of Translational Medicine</i> , 2013 , 11, 161	8.5	25
133	Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort. <i>European Journal of Cancer</i> , 2013 , 49, 2134-42	7.5	55
132	Hypercastration in prostate cancer. <i>Expert Review of Endocrinology and Metabolism</i> , 2013 , 8, 303-305	4.1	1

131	EGFR mutational status in penile cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2013 , 17, 501-5	6.4	12
130	Combined magnetic resonance spectroscopy and dynamic contrast-enhanced imaging for prostate cancer detection. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013 , 31, 761-5	2.8	14
129	Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design. <i>Clinical Genitourinary Cancer</i> , 2013 , 11, 495-500	3.3	16
128	Metabolic syndrome as a peculiar target for management of prostate cancer patients. <i>Clinical Genitourinary Cancer</i> , 2013 , 11, 211-20	3.3	14
127	The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy. <i>Critical Reviews in Oncology/Hematology</i> , 2013 , 86, 42-51	7	36
126	Management of castrate resistant prostate cancer-recent advances and optimal sequence of treatments. <i>Current Urology Reports</i> , 2013 , 14, 174-83	2.9	13
125	Tumor-to-tumor metastasis: breast cancer metastatic to thymic epithelial tumor. <i>Anti-Cancer Drugs</i> , 2013 , 24, 759-64	2.4	4
124	Comment on: EGFR mutational status in Brazilian patients with penile carcinoma. <i>Expert Opinion on Therapeutic Targets</i> , 2013 , 17, 857-9	6.4	2
123	Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2013 , 9, 889-97	3.6	27
122	Penile cancer: current therapy and future directions. <i>Annals of Oncology</i> , 2013 , 24, 1179-89	10.3	61
121	Peg-filgrastim and cabazitaxel in prostate cancer patients. <i>Anti-Cancer Drugs</i> , 2013 , 24, 84-9	2.4	22
120	Combined chemo-radiotherapy in locally advanced nasopharyngeal carcinomas. <i>World Journal of Clinical Oncology</i> , 2013 , 4, 47-51	2.5	11
119	Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml. <i>PLoS ONE</i> , 2013 , 8, e67687	3.7	71
118	Health-related quality of life in Parkinson's disease patients in northeastern Sicily, Italy: (An ecological perspective). <i>Neural Regeneration Research</i> , 2013 , 8, 1615-22	4.5	2
117	Non-AIDS-related Kaposi's sarcoma: A single-institution experience. <i>World Journal of Clinical Oncology</i> , 2013 , 4, 52-7	2.5	8
116	Prognostic factors and validation of prognostic nomograms in patients (pts) treated with three targeted therapies (TTs) for metastatic renal cell carcinoma (mRCC): Results from an Italian survey.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 470-470	2.2	
115	Which data for cabazitaxel (Cbz) from the real world? The safety experience from the Italian centres participating in the Expanded Access Programme (EAP).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 189-189	2.2	
114	Progression-free survival (PFS) and overall survival (OS) in patients receiving three targeted therapies (TTs) for metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 431-431 ^{2,2}		1

113	Impact of response to prior chemotherapy (RTPC) on outcomes in second-line therapy for advanced urothelial carcinoma (UC): Implications for trial design.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4539-4539 ^{2,2}		
112	Capecitabine-gemcitabine in thymic epithelial tumors.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e18536-e18536		
111	Thymic epithelial tumors at University Federico II of Naples: A 30-year experience.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 7603-7603	2.2	
110	Potential predictive and prognostic factors for sequential treatment with abiraterone acetate and cabazitaxel in metastatic docetaxel-refractory castration-resistant prostate cancer (mDR-CRPC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, e16093-e16093	2.2	
109	Clinical outcome (CO) and predictive factors (PRE) evaluation of young (≤60 years) castration-resistant prostate cancer (CRPC) patients, treated with docetaxel (DOC): Preliminary results of an Italian multicenter retrospective study (CYCLOP study).. <i>Journal of Clinical Oncology</i> , 2013 , 31, e16031-e16031	2.2	
108	The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature. <i>European Urology</i> , 2012 , 61, 639-47	10.2	24
107	Sipuleucel-T (Provenge®) for castration-resistant prostate cancer. <i>BJU International</i> , 2012 , 110, E99-104	5.6	34
106	Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey. <i>BJU International</i> , 2012 , 110, 692-8	5.6	37
105	Imatinib mesylate in thymic epithelial malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 69, 309-15	3.5	35
104	Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis. <i>BJU International</i> , 2012 , 110, E661-6	5.6	47
103	Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers. <i>Clinica Chimica Acta</i> , 2012 , 413, 1274-8	6.2	48
102	Preoperative insulin-like growth factor-binding protein-3 (IGFBP-3) blood level predicts gleason sum upgrading. <i>Prostate</i> , 2012 , 72, 100-7	4.2	12
101	Chondroitin sulphate enhances the antitumor activity of gemcitabine and mitomycin-C in bladder cancer cells with different mechanisms. <i>Oncology Reports</i> , 2012 , 27, 409-15	3.5	13
100	How to carry out retrospective studies in metastatic renal cell cancer: two caveats that should be avoided. <i>Expert Review of Anticancer Therapy</i> , 2012 , 12, 331-3	3.5	1
99	Authors reply: an adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 1079-1080	4	2
98	Combination of docetaxel and cetuximab for penile cancer: a case report and literature review. <i>Anti-Cancer Drugs</i> , 2012 , 23, 573-7	2.4	26
97	New perspectives in the therapy of castration resistant prostate cancer. <i>Current Drug Targets</i> , 2012 , 13, 1676-86	3	28
96	Numerical Study of Laminar Confined Impinging Slot Jets with Nanofluids. <i>Advances in Mechanical Engineering</i> , 2012 , 4, 248795	1.2	9

95	Preliminary safety results of an Italian early-access program (EAP) with cabazitaxel plus prednisone (CbzP) in patients with docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 253-253	2.2	3
94	Everolimus plus long-acting somatostatin analogs in thymic epithelial malignancies. <i>World Journal of Clinical Oncology</i> , 2012 , 3, 111-5	2.5	9
93	Decision making in clinical stage I (CSI) testicular cancer (TC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, e15034-e15034	2.4	10
92	The burden of illness in metastatic renal cell carcinoma (mRCC) patients after two targeted therapies: A review of the literature.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e15043-e15043	2.2	
91	Updated safety result of a large Italian early access program (EAP) with cabazitaxel plus prednisone (CbzP) in metastatic castration-resistant prostate cancer (mCRPC) patients who progressed during or after docetaxel (D) therapy.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e15185-e15185	2.2	
90	Update on PEG-interferon α 2b as adjuvant therapy in melanoma. <i>Anticancer Research</i> , 2012 , 32, 3901-9	2.3	10
89	Economic evaluation of everolimus versus sorafenib for the treatment of metastatic renal cell carcinoma after failure of first-line sunitinib. <i>Value in Health</i> , 2011 , 14, 846-51	3.3	21
88	Immunotherapy for the treatment of prostate cancer. <i>Nature Reviews Clinical Oncology</i> , 2011 , 8, 551-61	19.4	74
87	Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer. <i>BJU International</i> , 2011 , 107, 234-9	5.6	71
86	A comprehensive outlook on intracerebral therapy of malignant gliomas. <i>Critical Reviews in Oncology/Hematology</i> , 2011 , 80, 54-68	7	70
85	Prostate cancer detection in the "grey area" of prostate-specific antigen below 10 ng/ml: head-to-head comparison of the updated PCPT calculator and ChunH nomogram, two risk estimators incorporating prostate cancer antigen 3. <i>European Urology</i> , 2011 , 59, 81-7	10.2	59
84	Toxicities of targeted therapy and their management in kidney cancer. <i>European Urology</i> , 2011 , 59, 526-40	10.2	89
83	Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study. <i>European Urology</i> , 2011 , 60, 1280-4	10.2	48
82	Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 67, 1455-61	3.5	22
81	Sipuleucel-T for prostate cancer: the immunotherapy era has commenced. <i>Expert Review of Anticancer Therapy</i> , 2011 , 11, 25-8	3.5	25
80	Anaplastic thyroid carcinoma: A comprehensive review of current and future therapeutic options. <i>World Journal of Clinical Oncology</i> , 2011 , 2, 150-7	2.5	69
79	An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples. <i>Expert Opinion on Pharmacotherapy</i> , 2011 , 12, 1491-7	4	20
78	Soluble interleukin-6 receptor to interleukin-6 (sIL-6R/IL-6) ratio in serum as a predictor of high Gleason sum at radical prostatectomy. <i>Oncology Letters</i> , 2011 , 2, 861-864	2.6	4

77	Locally advanced nasopharyngeal carcinoma: Current and emerging treatment strategies. <i>World Journal of Clinical Oncology</i> , 2011 , 2, 377-83	2.5	31
76	Effects of the ErbB1/ErbB2 kinase inhibitor GW2974 on androgen-independent prostate cancer PC-3 cell line growth and NSE, chromogranin A and osteopontin content. <i>Oncology Reports</i> , 2010 , 24, 213-7	3.5	5
75	Preliminary results of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs). <i>Annals of Oncology</i> , 2010 , 21, 1168-1172	10.3	35
74	Re: Sequential sorafenib and sunitinib for renal cell carcinoma M. P. Sablin, S. Negrier, A. Ravaud, S. Oudard, C. Balleyguier, J. Gautier, C. Celier, J. Medioni and B. Escudier <i>J Urol</i> 2009; 182: 29-34. <i>Journal of Urology</i> , 2010 , 183, 824-5; author reply 825	2.5	
73	Castration-resistant prostate cancer: current and emerging treatment strategies. <i>Drugs</i> , 2010 , 70, 983-1000	10.0	77
72	Editorial comment. Correlation between serum prostate-specific antigen and cancer volume in prostate glands of different sizes. <i>Urology</i> , 2010 , 76, 1076; author reply 1076-7	1.6	
71	The therapy of kidney cancer with biomolecular drugs. <i>Cancer Treatment Reviews</i> , 2010 , 36 Suppl 3, S16-20	2.4	29
70	Is gemcitabine an option in BCG-refractory nonmuscle-invasive bladder cancer? A single-arm prospective trial. <i>Anti-Cancer Drugs</i> , 2010 , 21, 101-6	2.4	14
69	Ten-year adjuvant treatment with somatostatin analogs in a patient with atypical carcinoid of the lung. <i>Anti-Cancer Drugs</i> , 2010 , 21, 465-8	2.4	4
68	Matrix metalloproteinase-2 and -9 in the urine of prostate cancer patients. <i>Oncology Reports</i> , 2010 , 24, 3-8	3.5	15
67	BAG3 protein delocalisation in prostate carcinoma. <i>Tumor Biology</i> , 2010 , 31, 461-9	2.9	30
66	Can high-dose fotemustine reverse MGMT resistance in glioblastoma multiforme?. <i>Journal of Neuro-Oncology</i> , 2010 , 100, 311-9	4.8	4
65	Docetaxel rechallenge in castration-resistant prostate cancer: scientific legitimacy of common clinical practice. <i>European Urology</i> , 2010 , 58, 636-7	10.2	22
64	Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma. <i>European Urology</i> , 2010 , 58, 906-11	10.2	48
63	Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial. <i>Cancer</i> , 2010 , 116, 1893-900	6.4	102
62	Pathological complete response induced by first-line chemotherapy with single agent docetaxel in a patient with advanced non small cell lung cancer. <i>World Journal of Surgical Oncology</i> , 2010 , 8, 8	3.4	2
61	Efficacy of rituximab in gastric diffuse large B cell lymphoma patients. <i>World Journal of Gastroenterology</i> , 2010 , 16, 2526-30	5.6	25
60	Thalidomide and Analogs 2010 , 215-223		

59	Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. <i>Annals of Oncology</i> , 2009 , 20, 1535-1542	10.3	155
58	Targeted therapy in the treatment of metastatic renal cell cancer. <i>Oncology</i> , 2009 , 77 Suppl 1, 122-31	3.6	4
57	Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4469-74	2.2	114
56	Pathology of the prostate in radical cystectomy specimens: a critical review. <i>Surgical Oncology</i> , 2009 , 18, 73-84	2.5	21
55	Four-year outcome of a prospective randomised trial comparing bipolar plasmakinetic and monopolar transurethral resection of the prostate. <i>European Urology</i> , 2009 , 55, 922-9	10.2	81
54	Metastatic renal cell carcinoma: recent advances in the targeted therapy era. <i>European Urology</i> , 2009 , 56, 959-71	10.2	47
53	Phase 1/2 study of intravenous paclitaxel and oral cyclophosphamide in pretreated metastatic urothelial bladder cancer patients. <i>Cancer</i> , 2009 , 115, 517-23	6.4	18
52	Short-term administration of prulifloxacin in patients with nonmuscle-invasive bladder cancer: an effective option for the prevention of bacillus Calmette-Guérin-induced toxicity?. <i>BJU International</i> , 2009 , 104, 633-9	5.6	20
51	Looking at the prostates of patients with bladder cancer: a thoughtful exercise. <i>BJU International</i> , 2009 , 104, 160-2	5.6	1
50	Health related quality of life after radical cystectomy: comparison of ileal conduit to continent orthotopic neobladder. <i>European Journal of Surgical Oncology</i> , 2009 , 35, 858-64	3.6	52
49	Combination of perianal-intrarectal lidocaine-prilocaine cream and periprostatic nerve block for pain control during transrectal ultrasound guided prostate biopsy: a randomized, controlled trial. <i>Journal of Urology</i> , 2009 , 181, 585-91; discussion 591-3	2.5	53
48	Activity and toxicity of paclitaxel in pretreated metastatic penile cancer patients. <i>Anti-Cancer Drugs</i> , 2009 , 20, 277-80	2.4	7
47	Activity and safety of pegylated liposomal doxorubicin as first-line therapy in the treatment of non-visceral classic Kaposi sarcoma: a multicenter study. <i>Journal of Investigative Dermatology</i> , 2008 , 128, 1578-80	4.3	44
46	Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. <i>European Urology</i> , 2008 , 54, 1089-94	10.2	106
45	Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer. <i>Breast Cancer Research</i> , 2008 , 10, R60	8.3	47
44	What happens to the abstracts presented at the Société Internationale d'Urologie meeting?. <i>Urology</i> , 2008 , 71, 367-71	1.6	17
43	Update on classic Kaposi sarcoma therapy: new look at an old disease. <i>Critical Reviews in Oncology/Hematology</i> , 2008 , 68, 242-9	7	38
42	Bladder-sparing, combined-modality approach for muscle-invasive bladder cancer: a multi-institutional, long-term experience. <i>Cancer</i> , 2008 , 112, 75-83	6.4	70

41	Pegylated liposomal doxorubicin as second-line therapy in the treatment of patients with advanced classic Kaposi sarcoma: a retrospective study. <i>Cancer</i> , 2008 , 112, 1147-52	6.4	25
40	Re: Abstracts presented at the American Urological Association Annual Meeting: determinants of subsequent peer reviewed publication: C. C. Hoag, D. S. Elterman and A. E. MacNeily. <i>J Urol</i> 2006; 176: 2624-2629. Re: Factors associated with the full publication of studies presented in abstract form at the annual meeting of the American Urological Association. Smith WA, Cangel QV, Tseng TY, Sultan S, Wawonja J, Dahm P. <i>J Urol</i> 2007; 177: 1084-8. <i>Journal of Urology</i> , 2007, 178, 1124-5; author reply 1125	2.5	1
39	Hormone-refractory prostate cancer: where are we going?. <i>Drugs</i> , 2007 , 67, 1109-24	12.1	13
38	Are abstracts presented at the EAU meeting followed by publication in peer-reviewed journals? A critical analysis. <i>European Urology</i> , 2007 , 51, 833-40; discussion 840	10.2	51
37	Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study. <i>European Urology</i> , 2007 , 52, 1020-7	10.2	13
36	Re: Fabio Calabrand Cora N. Sternberg. Current indications for chemotherapy in prostate cancer patients. <i>Eur urol</i> 2007;51:17-26. <i>European Urology</i> , 2007 , 52, 613-4	10.2	1
35	Re: Björge Ljungberg, Damian C. Hanbury, Marcus A. Kuczyk, Axel S. Merseburger, Peter F.A. Mulders, Jean-Jaques Patard and Ioanel C. Sinescu. Renal cell carcinoma guideline. <i>Eur Urol</i> 2007;51:1502-10. <i>European Urology</i> , 2007 , 52, 926-8; author reply 928	10.2	
34	Clinicopathologic features of prostate adenocarcinoma incidentally discovered at the time of radical cystectomy: an evidence-based analysis. <i>European Urology</i> , 2007 , 52, 648-57	10.2	65
33	Thalidomide in combination with oral daily cyclophosphamide in patients with pretreated hormone refractory prostate cancer: a phase I clinical trial. <i>Cancer Biology and Therapy</i> , 2007 , 6, 313-7	4.6	28
32	Quantitative analysis of pursuit ocular movements in Parkinson's disease by using a video-based eye tracking system. <i>European Neurology</i> , 2007 , 58, 193-7	2.1	27
31	Phase II trial of gemcitabine, prednisone, and zoledronic acid in pretreated patients with hormone refractory prostate cancer. <i>Urology</i> , 2007 , 69, 347-51	1.6	12
30	Vesicourethral anastomosis during radical retropubic prostatectomy: does the number of sutures matter?. <i>Urology</i> , 2007 , 69, 547-51	1.6	20
29	Management of AIDS-related Kaposi's sarcoma. <i>Lancet Oncology, The</i> , 2007 , 8, 167-76	21.7	101
28	Estramustine in prostate cancer: new look at an old drug. <i>Lancet Oncology, The</i> , 2007 , 8, 959-61	21.7	2
27	Activity and safety of pegylated liposomal doxorubicin, 5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma: A phase II study. <i>World Journal of Gastroenterology</i> , 2007 , 13, 6553	5.6	4
26	Role of dynamic sentinel node biopsy in penile cancer: our experience. <i>Journal of Surgical Oncology</i> , 2006 , 93, 181-5	2.8	21
25	Gynecomastia in patients with prostate cancer: update on treatment options. <i>Prostate Cancer and Prostatic Diseases</i> , 2006 , 9, 109-14	6.2	19
24	Medical expulsive treatment of distal-ureteral stones using tamsulosin: a single-center experience. <i>Journal of Endourology</i> , 2006 , 20, 12-6	2.7	104

23	Gyrus bipolar versus standard monopolar transurethral resection of the prostate: a randomized prospective trial. <i>Urology</i> , 2006 , 67, 69-72	1.6	97
22	Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial. <i>Lancet Oncology, The</i> , 2005 , 6, 295-300	21.7	82
21	Management of gynaecomastia in patients with prostate cancer: a systematic review. <i>Lancet Oncology, The</i> , 2005 , 6, 972-9	21.7	34
20	How to decrease pain during transrectal ultrasound guided prostate biopsy: a look at the literature. <i>Journal of Urology</i> , 2005 , 174, 2091-7	2.5	84
19	Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy. <i>Journal of Urology</i> , 2005 , 174, 2197-203	2.5	43
18	Dynamic sentinel node biopsy in clinically node-negative penile cancer versus radical inguinal lymphadenectomy: a comparative study. <i>Urology</i> , 2005 , 66, 1282-6	1.6	53
17	The need to reduce patient discomfort during transrectal ultrasonography-guided prostate biopsy: what do we know?. <i>BJU International</i> , 2005 , 96, 977-83	5.6	45
16	Pegylated liposomal doxorubicin in stage IVB mycosis fungoides. <i>British Journal of Dermatology</i> , 2005 , 153, 183-5	4	23
15	Recovery of erection after pelvic urologic surgery: our experience. <i>International Journal of Impotence Research</i> , 2005 , 17, 484-93	2.3	18
14	The use of tamsulosin in the medical treatment of ureteral calculi: where do we stand?. <i>Urological Research</i> , 2005 , 33, 460-4		70
13	Prospective clinical trials of biotherapies in solid tumors: a 5-year survey. <i>Cancer Immunology, Immunotherapy</i> , 2005 , 54, 44-50	7.4	12
12	Expression of biomarkers modulating prostate cancer progression: implications in the treatment of the disease. <i>Prostate Cancer and Prostatic Diseases</i> , 2005 , 8, 54-9	6.2	27
11	FOLFOX-4 in pre-treated patients with advanced transitional cell carcinoma of the bladder. <i>Japanese Journal of Clinical Oncology</i> , 2004 , 34, 747-50	2.8	24
10	Weekly docetaxel and vinorelbine (VIN-DOX) as first line treatment in patients with hormone refractory prostate cancer. <i>European Urology</i> , 2004 , 46, 712-6	10.2	14
9	Expression of proto-oncogene c-kit in high risk prostate cancer. <i>European Journal of Surgical Oncology</i> , 2004 , 30, 987-92	3.6	30
8	Is There a Standard Chemotherapeutic Regimen for Hormone-Refractory Prostate Cancer? Present and Future Approaches in the Management of the Disease. <i>Tumori</i> , 2003 , 89, 349-360	1.7	5
7	Adrenal sparing surgery in the treatment of renal cell carcinoma: when is it possible?. <i>World Journal of Urology</i> , 2003 , 21, 153-8	4	17
6	Are extended biopsies really necessary to improve prostate cancer detection?. <i>Prostate Cancer and Prostatic Diseases</i> , 2003 , 6, 250-5	6.2	17

5	Involvement of growth factor receptors of the epidermal growth factor receptor family in prostate cancer development and progression to androgen independence. <i>Clinical Prostate Cancer</i> , 2003 , 2, 50-7		49
4	Statistical design in phase II clinical trials and its application in breast cancer. <i>Lancet Oncology, The</i> , 2003 , 4, 305-11	21.7	22
3	Adrenalectomy: defining its role in the surgical treatment of renal cell carcinoma. <i>Urologia Internationalis</i> , 2003 , 71, 361-7	1.9	9
2	Role of chemotherapy in hormone-refractory prostate cancer. Old issues, recent advances and new perspectives. <i>Urologia Internationalis</i> , 2003 , 70, 1-14	1.9	13
1	Is there a standard chemotherapeutic regimen for hormone-refractory prostate cancer? Present and future approaches in the management of the disease. <i>Tumori</i> , 2003 , 89, 349-60	1.7	2